Menu
Back to Journals » International Medical Case Reports Journal » Volume 3
Sorafenib in metastatic MTC – a case report and minireview of the literature
Authors Petrova M, Mihaylova Z, Fakirova A
Published 27 May 2010 Volume 2010:3 Pages 55—58
DOI https://doi.org/10.2147/IMCRJ.S9384
Review by Single anonymous peer review
Peer reviewer comments 2
Mila Petrova1, Zhasmina Mihaylova1, Albena Fakirova2
1Hematology and Oncology Department, 2Pathology Department, Medical Military Academy, Sofia, Bulgaria
Abstract: Medullary thyroid cancer (MTC) is a rare and only surgically treatable disease with early development of metastases and bad prognosis. Due to the lack of efficient systemic treatment, new strategies and approaches are needed to better the patients’ outcome. One of the most promising treatment options is the use of tyrosine multikinase inhibitors, which appear to have some effect on the disease progression with tolerable toxicity. Most of them affect many key pathways in the cancer genesis and have proven their effect in different malignancies. We report a case of a young patient with metastatic MTC treated successfully for two months with sorafenib.
Keywords: medullary thyroid cancer, tumor response, cardiotoxicity, TKIs
© 2010 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.